{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:18:52Z","timestamp":1792649932817,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.xphs.2022.07.012","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T22:45:34Z","timestamp":1658443534000},"page":"2917-2929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-2452","authenticated-orcid":false,"given":"Sarah","family":"Alrubia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1497-3140","authenticated-orcid":false,"given":"Zubida M.","family":"Al-Majdoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-5626","authenticated-orcid":false,"given":"Brahim","family":"Achour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3917-844X","authenticated-orcid":false,"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5424-0291","authenticated-orcid":false,"given":"Jill","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.07.012_bib0001","article-title":"Inflammatory responses and inflammation-associated diseases in organs","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.xphs.2022.07.012_bib0002","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn disease: epidemiology, diagnosis, and management","volume":"92","author":"Feuerstein","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0003","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1208\/s12248-016-9889-y","article-title":"Gut wall metabolism. Application of pre-clinical models for the prediction of human drug absorption and first-pass elimination","volume":"18","author":"Jones","year":"2016","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.xphs.2022.07.012_bib0004","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/jcph.1093","article-title":"Disease-Drug Interactions in Inflammatory States via Effects on CYP-mediated drug clearance","volume":"58","author":"Coutant","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2022.07.012_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MIB.0000000000000029","article-title":"Epithelial transport in inflammatory bowel diseases","volume":"20","author":"Ghishan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/01480549709003891","article-title":"First-pass effect: significance of the intestine for absorption and metabolism","volume":"20","author":"Doherty","year":"1997","journal-title":"Drug Chem Toxicol"},{"issue":"8","key":"10.1016\/j.xphs.2022.07.012_bib0007","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/dmd.119.086959","article-title":"The regional-specific relative and absolute expression of gut transporters in adult caucasians: a meta-analysis","volume":"47","author":"Harwood","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0008","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.dmpk.2017.11.250","article-title":"Protein abundance of pharmacokinetically relevant transporter proteins and metabolizing enzymes along the human intestine and in the liver: A comparative intra-subject study","volume":"33","author":"Bradbury","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2022.07.012_bib0009","series-title":"Enhancing the Diversity of Clinical Trial Populations \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry","year":"2020"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2022.07.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-022-01169-4","article-title":"Altered bioavailability and pharmacokinetics in crohn's disease: capturing systems parameters for PBPK to assist with predicting the fate of orally administered drugs","author":"Alrubia","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.xphs.2022.07.012_bib0012","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1053\/j.gastro.2007.08.041","article-title":"Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation","volume":"133","author":"Thibault","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/jpet.119.262972","article-title":"Profiling of Drug-Metabolizing Enzymes and Transporters in Human Tissue Biopsy Samples: A Review of the Literature","volume":"372","author":"Rodrigues","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.xphs.2022.07.012_bib0014","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1124\/dmd.109.027367","article-title":"Changes in mrna expression levels of solute carrier transporters in inflammatory bowel disease patients","volume":"37","author":"Wojtal","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"51","key":"10.1016\/j.xphs.2022.07.012_bib0015","doi-asserted-by":"crossref","first-page":"35630","DOI":"10.1074\/jbc.M804374200","article-title":"Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease","volume":"283","author":"Blokzijl","year":"2008","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.xphs.2022.07.012_bib0016","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.molpharmaceut.9b00459","article-title":"Crohn's disease is associated with decreased CYP3A4 and P-glycoprotein protein expression","volume":"16","author":"Wilson","year":"2019","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2022.07.012_bib0017","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ibd.20088","article-title":"Decreased P-glycoprotein (P-gp\/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels","volume":"13","author":"Blokzijl","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0018","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/2000-1967-203","article-title":"Expression of cytochrome P450 and MDR1 in patients with proctitis","volume":"112","author":"Th\u00f6rn","year":"2007","journal-title":"Ups J Med Sci"},{"issue":"9","key":"10.1016\/j.xphs.2022.07.012_bib0019","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1124\/dmd.114.058065","article-title":"Inflammatory bowel disease alters intestinal bile acid transporter expression","volume":"42","author":"Jahnel","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.prp.2013.12.010","article-title":"Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions","volume":"210","author":"Plewka","year":"2014","journal-title":"Pathol - Res Pract"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/ng1339","article-title":"Functional variants of OCTN cation transporter genes are associated with Crohn disease","volume":"36","author":"Peltekova","year":"2004","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.53.1.78","article-title":"Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor","volume":"53","author":"Jung","year":"2004","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","article-title":"Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes","volume":"127","author":"Langmann","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0024","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1124\/dmd.120.000283","article-title":"In vivo gene expression profile of human intestinal epithelial cells: from the viewpoint of drug metabolism and pharmacokinetics","volume":"49","author":"Takayama","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2022.07.012_bib0025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0011-393X(98)85095-9","article-title":"Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease","volume":"59","author":"Klotz","year":"1998","journal-title":"Curr Ther Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.07.012_bib0026","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.crohns.2011.08.003","article-title":"Expression and functional analysis of intestinal organic cation\/l-carnitine transporter (OCTN) in Crohn's Disease","volume":"6","author":"Girardin","year":"2012","journal-title":"J Crohn's Colitis"},{"issue":"8","key":"10.1016\/j.xphs.2022.07.012_bib0027","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/dmd.121.000484","article-title":"Proteomic quantification of changes in abundance of drug-metabolizing enzymes and drug transporters in human liver cirrhosis: different methods, similar outcomes","volume":"49","author":"El-Khateeb","year":"2021","journal-title":"drug metab dispos"},{"key":"10.1016\/j.xphs.2022.07.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104601","article-title":"Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease","volume":"263","author":"Vasilogianni","year":"2022","journal-title":"J Proteomics"},{"key":"10.1016\/j.xphs.2022.07.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107397","article-title":"Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice","volume":"203","author":"El-Khateeb","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.xphs.2022.07.012_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpba.2015.02.043","article-title":"Application of an LC-MS\/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique","volume":"110","author":"Harwood","year":"2015","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0031","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1021\/pr400667h","article-title":"Quantification of the proteins of the bacterial ribosome using QconCAT technology","volume":"13","author":"Al-Majdoub","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.xphs.2022.07.012_bib0032","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ab.2018.03.019","article-title":"Quantification of proteins by data independent acquisition: Performance assessment of the Hi3 methodology","volume":"549","author":"Chevreux","year":"2018","journal-title":"Anal Biochem"},{"issue":"8","key":"10.1016\/j.xphs.2022.07.012_bib0033","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/acs.molpharmaceut.6b00085","article-title":"Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects","volume":"13","author":"Miyauchi","year":"2016","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0034","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cpt.2097","article-title":"Quantification of proteins involved in intestinal epithelial handling of xenobiotics","volume":"109","author":"Al-Majdoub","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0035","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cpt.2097","article-title":"Quantification of proteins involved in intestinal epithelial handling of xenobiotics","volume":"109","author":"Al-Majdoub","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.xphs.2022.07.012_bib0036","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.120.090738","article-title":"Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine","volume":"48","author":"Zhang","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0037","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.1301","article-title":"Protein abundance of clinically relevant drug transporters in the human liver and intestine: a comparative analysis in paired tissue specimens","volume":"105","author":"Drozdzik","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt.967","article-title":"Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens","volume":"104","author":"Drozdzik","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0039","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","article-title":"A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules","volume":"17","author":"Edsb\u00e4cker","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2036.1990.tb00496.x","article-title":"Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers","volume":"4","author":"Norlander","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0041","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2125.2011.04019.x","article-title":"Drug\u2212disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity","volume":"72","author":"Sanaee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0042","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MIB.0000000000001062","article-title":"CYP3A4 activity is markedly lower in patients with Crohn\u02bcs disease","volume":"23","author":"Wilson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0043","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2125.1979.tb05907.x","article-title":"Plasma propranolol concentrations and the erythrocyte sedimentation rate","volume":"8","author":"Schneider","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"10114","key":"10.1016\/j.xphs.2022.07.012_bib0044","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and Chemical Toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0046","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jmb.2010.01.075","article-title":"Structural Basis of Human CYP51 Inhibition by Antifungal Azoles","volume":"397","author":"Strushkevich","year":"2010","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0047","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common Human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Gagn\u00e9","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2022.07.012_bib0048","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bcp.2008.07.006","article-title":"The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan","volume":"76","author":"Alonen","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0049","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/08927022.2015.1044451","article-title":"Predicting substrate selectivity between UGT1A9 and UGT1A10 using molecular modelling and molecular dynamics approach","volume":"42","author":"Tripathi","year":"2016","journal-title":"Mol Simul"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfj061","article-title":"Human sulfotransferases and their role in chemical metabolism","volume":"90","author":"Gamage","year":"2006","journal-title":"Toxicol Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0051","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/gut.2007.128868","article-title":"Role of alkaline phosphatase in colitis in man and rats","volume":"58","author":"Tuin","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0052","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.apsb.2011.08.001","article-title":"Enzyme-mediated hydrolytic activation of prodrugs","volume":"1","author":"Yang","year":"2011","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0053","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/BJ20051988","article-title":"Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases\/reductases and aldo-keto reductases with retinoids","volume":"399","author":"Gallego","year":"2006","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0054","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/hmg\/8.5.743","article-title":"Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-Linked Sideroblastic Anemia and Ataxia (XLSA\/A)","volume":"8","author":"Allikmets","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0092-8674(00)81370-7","article-title":"MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine","volume":"87","author":"van Helvoort","year":"1996","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.xphs.2022.07.012_bib0056","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1074\/jbc.272.9.5974","article-title":"Multidrug-resistant human sarcoma cells with a mutant p-glycoprotein, altered phenotype, and resistance to cyclosporins","volume":"272","author":"Chen","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0057","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","article-title":"ABCG2: determining its relevance in clinical drug resistance","volume":"26","author":"Robey","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"10.1016\/j.xphs.2022.07.012_bib0058","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.bbadis.2012.02.009","article-title":"Peroxisomal ABC transporters: Structure, function and role in disease","volume":"1822","author":"Morita","year":"2012","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"23","key":"10.1016\/j.xphs.2022.07.012_bib0059","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1002\/1873-3468.13982","article-title":"Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin","volume":"594","author":"Al-Majdoub","year":"2020","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/j.xphs.2022.07.012_bib0060","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0061","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/157340910790980133","article-title":"Bioavailability through PepT1: the role of computer modelling in intelligent drug design","volume":"6","author":"Foley","year":"2010","journal-title":"Curr Comput Aided-Drug Des"},{"issue":"2-3","key":"10.1016\/j.xphs.2022.07.012_bib0062","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.mam.2012.11.005","article-title":"The heteromeric organic solute transporter, OST\u03b1\u2013OST\u03b2\/SLC51: A transporter for steroid-derived molecules","volume":"34","author":"Ballatori","year":"2013","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.xphs.2022.07.012_bib0063","doi-asserted-by":"crossref","DOI":"10.1097\/00054725-200810001-00068","article-title":"What is the effect of inflammation on intestinal function?","author":"Barbara","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.xphs.2022.07.012_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/S0889-8553(21)00207-7","article-title":"Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease","author":"Sartor","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/ecp.11.66","article-title":"Inflammation-mediated changes in drug transporter expression\/activity: implications for therapeutic drug response","volume":"5","author":"Cressman","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2022.07.012_bib0066","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450\u2013mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0067","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpt.128","article-title":"Understanding disease-drug interactions in cancer patients: Implications for dosing within the therapeutic window","volume":"98","author":"Coutant","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0068","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO;2-L","article-title":"Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells","volume":"90","author":"Bertilsson","year":"2001","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.07.012_bib0069","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2022.07.012_bib0070","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of Interleukin-6 (IL-6) and an Anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2022.07.012_bib0071","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0006-2952(98)00372-4","article-title":"Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy","volume":"57","author":"Elkahwaji","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2022.07.012_bib0072","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J Clin Invest"},{"issue":"10-11","key":"10.1016\/j.xphs.2022.07.012_bib0073","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1080\/00498250600861827","article-title":"Nuclear receptors CAR and PXR in the regulation of hepatic metabolism","volume":"36","author":"Tien","year":"2006","journal-title":"Xenobiotica"},{"issue":"18","key":"10.1016\/j.xphs.2022.07.012_bib0074","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.1074\/jbc.M010173200","article-title":"Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin","volume":"276","author":"Geick","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jfda.2018.11.005","article-title":"The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders","volume":"27","author":"Wu","year":"2019","journal-title":"J Food Drug Anal"},{"issue":"16","key":"10.1016\/j.xphs.2022.07.012_bib0076","doi-asserted-by":"crossref","first-page":"11784","DOI":"10.1074\/jbc.275.16.11784","article-title":"Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde","volume":"275","author":"Nebert","year":"2000","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.xphs.2022.07.012_bib0077","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/dmd.110.035121","article-title":"Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids","volume":"39","author":"Bui","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.xphs.2022.07.012_bib0078","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jhg.2014.77","article-title":"GST Theta null genotype is associated with an increased risk for ulcerative colitis: a case\u2013control study and meta-analysis of GST Mu and GST Theta polymorphisms in inflammatory bowel disease","volume":"59","author":"Broekman","year":"2014","journal-title":"J Hum Genet"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-62872-5","article-title":"The DsbA-L gene is associated with respiratory function of the elderly via its adiponectin multimeric or antioxidant properties","volume":"10","author":"Oniki","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2022.07.012_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/9074601","article-title":"The role of intestinal alkaline phosphatase in inflammatory disorders of gastrointestinal tract","volume":"2017","author":"Bilski","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.xphs.2022.07.012_bib0081","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bpg.2016.02.007","article-title":"Physiology of intestinal absorption and secretion","volume":"30","author":"Kiela","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2-3","key":"10.1016\/j.xphs.2022.07.012_bib0082","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0169-409X(97)00041-0","article-title":"The barrier function of CYP3A4 and P-glycoprotein in the small bowel","volume":"27","author":"Watkins","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"issue":"2-3","key":"10.1016\/j.xphs.2022.07.012_bib0083","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0168-3659(95)00147-6","article-title":"Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery","volume":"39","author":"Benet","year":"1996","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2022.07.012_bib0084","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/mp900253n","article-title":"The drug transporter\u2212metabolism alliance: uncovering and defining the interplay","volume":"6","author":"Benet","year":"2009","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2022.07.012_bib0085","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/jps.21572","article-title":"Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption","volume":"98","author":"Badhan","year":"2009","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.07.012_bib0086","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1018872207437","article-title":"Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption\u2013theoretical approach","volume":"16","author":"Ito","year":"1999","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2022.07.012_bib0087","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1124\/jpet.300.3.1036","article-title":"Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4","volume":"300","author":"Cummins","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2022.07.012_bib0088","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/jpet.103.058065","article-title":"CYP3A4-Transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam","volume":"308","author":"Cummins","year":"2004","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922003033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922003033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:37:16Z","timestamp":1764121036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922003033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0022354922003033"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.07.012","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}